ESMO Preceptorship Programme Brain tumors – Athens – 28-29 september Tarek ASSI Institut Gustave ROUSSY - Paris Long term response to Bevacizumab to an initially resistant glioblastoma
No conflict of interests ESMO PRECEPTORSHIP PROGRAMME
Initial Presentation Age : 38 years. History of diabetes and HTA. December 2011: Generalized seizure. Diagnosis of a parasagittal precentral frontal glioblastoma. Surgery performed with complete resection of the brain tumor. ESMO PRECEPTORSHIP PROGRAMME
Adjuvant Therapy January 2012: – STUPP protocol: • Radiotherapy of 60 Gy in 30 sessions • Temozolomide 150 mg per day during radiotherapy. • Received two cycles of Temozolomide 200 mg/m2 = 400 mg for 5 days every 4 weeks – After the second cycle = A new generalized seizure. ESMO PRECEPTORSHIP PROGRAMME
First relapse therapy MRI of the brain performed: – Multinodular increased contrast enhancement in the frontal lobe region. Decision to start Lomustine – Due to logistic issues: Procarbazine 60mg/m2 for 2 weeks every 4 weeks. • September 2012 (After 3 months), • Aphasia and somnolence • MRI : increased contrast enhancement with local frontal lobe progression. ESMO PRECEPTORSHIP PROGRAMME
Second relapse therapy Avastin 10mg/kg every 2 weeks at the dose of 770mg started on August 2012. – Initial decreased contrast enhancement with persistent response. After 4 cycles – After two years, increased proteinuria with decision to maintain Avastin at the dose of 15 mg/kg every 3 weeks – Persistent response for 3 years until September 2015 ESMO PRECEPTORSHIP PROGRAMME
Therapeutic Holiday September 2015 : Decision to start therapeutic holiday with surveillance and MRI every 3 months. September 2016 :Maintained stable disease MRI every 6 months. September 2017 : memory trouble MRI demonstrated increased contrast enhancement in the frontal lesion. ESMO PRECEPTORSHIP PROGRAMME
Third Relapse October 2017: status epilepticus – MRI : • an increased leptomeningeal contrast enhancement as well as in the superior region of the frontal lobe. – Surgery was revoked due to the multifocality of the lesions. – Admission to the critical care facility. – Right hemiplegia with conscience problems. – Improved conscience with adjustment of antiepileptic drugs. Rechallenge with Bevacizumab 15mg/kg every 3 weeks – After two cycles in January 2018 : Persistent hemiplegia but improved clinical status with decreased contrast enhancement on MRI. ESMO PRECEPTORSHIP PROGRAMME
ESMO Preceptorship Programme
Long Term Plan The Long Term Plan Published January 2019 Response in autumn
NSGO EARLY PHASE CLINICAL TRIALS UPDATE Niraparib and niraparib-bevacizumab
ERCOT Demand Response Paul Wattles, ERCOT Staff Long-Term Study Task Force
Characterizing the long-term PM 2.5 - mortality response function: Comparing
Preparing Long-term Care Facilities for COVID-19 Kara M. Jacobs Slifka, MD,
Long term vision for LArSoft: Overview Adam Lyon LArSoft Workshop 2019 25
COVID-19 FEDERAL RESPONSE Leveraging federal programs for immediate relief
Modeling of Short-Term Stimulation and Long-Term Operation of EGS Reservoirs
TITLE: Global trends, our journey and response AUTHOR: Adrian Orr CHIEF
South Burlington School District Proposed Long-Term Bond Why issue a long
Recovery After Stroke and Genetic Influences of Neuroplasticity Noel F. So,
Aphasia Centre of Ottawa Programs and Services 2081 Merivale Road, suite 300
Presentation Presentation Presentation Presentation Presentation Abstract
Stroke awareness Hannah Parrington Volunteering and Community Team- North
Efficacy of Language Games as Therapy for Post-Stroke Aphasia Louise Lander
Interactive e-Therapies for patients with schizophrenia or aphasia Alex Leff
Issues In Single-Subject Research K. P. Kearns ASHA CPRI 7.10.09 Data
Brittany Clark, M.S., CCC-SLP Manager of Youth & Adult Rehab
Available online at www.ijmrhs.com c a l R d i e e s M e a f o r
IMAGING IN ACUTE ISCHEMIC STROKE Timo Krings MD, PhD, FRCP (C) Professor of
Simple and Effective Text Simplification Using Semantic and Neural Methods
Title: Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome GeneReview